Pharmacological cardioversion with Refralon

ApprovedSmall molecule

NNational Medical Research Center for Cardiology, Ministry of Health of Russian Federation

Pharmacological cardioversion with Refralon is one of 40 small molecule programs targeting Atrial Flutter. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Atrial FlutterActive, not recruiting

Atrial FibrillationActive, not recruiting

Atrial FlutterApproved

Active, not recruiting

Atrial FibrillationPreclinical

Active, not recruiting

Competition

Competitive Landscape

376 competitors in Atrial Fibrillation

#DrugCompanyPhaseTrials

Pharmacological cardioversion with Refralon

NNational Medical Research Center for Cardiology, Ministry of Health of Russian Federation

Approved

1 2

Calquence

AstraZeneca

Preclinical

1 3

Rituxan

Calan

4 5

Brukinsa

BBeOne Medicines

Preclinical

1 6

Imbruvica

PPharmacyclics LLC.

Preclinical

1 7

Romazicon

CConrado Roberto Hoffmann Filho

Preclinical

1 8

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 9

Ondexxya

UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

Preclinical

1 10

Calcium

Eli Lilly

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Atrial Fibrillation1 trial

Refralon in Patients With Recurrence Paroxysmal and Persistent Forms of Atrial Fibrillation Who Underwent Catheter Ablation

Completed·NNational Medical Research Center for Cardiology, Ministry of Health of Russian Federation·N/A·NCT05456204·120 enrolled

Atrial Flutter1 trial

Refralon Versus Amiodarone for Cardioversion of Paroxysmal Fibrillation and Atrial Flutter

Completed·NNational Medical Research Center for Cardiology, Ministry of Health of Russian Federation·Phase 4·NCT05445297·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Pharmacological cardioversion with Refralon. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pharmacological cardioversion with Refralon compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pharmacological cardioversion with Refralon. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Medical Research Center for Cardiology, Ministry of Health of Russian Federation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: NNational Medical Research Center for Cardiology, Ministry of Health of Russian Federation

Pharmacological cardioversion with Refralon

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Atrial Fibrillation1 trial

Atrial Flutter1 trial

References

Drug Info

Quick Facts

Related News